Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT ID: NCT06621602
Last Updated: 2026-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2024-12-17
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
NCT04518059
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
NCT01380899
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
NCT07217054
Diagnostic and Prognostic Biomarkers in Parkinson Disease
NCT00653783
Biomarker Analysis for GBA Associated Parkinson's Disease
NCT03811496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinical confirmed diagnosis of Parkinson's disease or REM Sleep Behavior
Exclusion Criteria
2. History of allergic reaction to Lidocaine for local anesthesia needed for skin biopsies
3. Use of blood thinners (Plavix or Aspirin used separately is allowed)
4. Significantly impaired wound healing or history of scarring or keloid formation
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Michael J. Fox Foundation for Parkinson's Research
OTHER
CND Life Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Todd Levine
Role: PRINCIPAL_INVESTIGATOR
CND Life Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CND Life Sciences
Scottsdale, Arizona, United States
Movement Disorders Center of Arizona
Scottsdale, Arizona, United States
Parkinson's Research Centers of America - Orange County
Aliso Viejo, California, United States
Cedars Sinai
Los Angeles, California, United States
Parkinson's Research Centers of America - Palo Alto
Palo Alto, California, United States
University of Colorado
Aurora, Colorado, United States
Aventura Neurologic Associates, LLC
Aventura, Florida, United States
Parkinson's Disease and Movement Disorders Center - Boca Raton
Boca Raton, Florida, United States
Atlanta NeuroScience Institute ANI
Atlanta, Georgia, United States
Parkinson's Disease and Movement Disorders Center at KUMC
Kansas City, Kansas, United States
Neurology Multidisciplinary Clinic at Norton Healthcare
Louisville, Kentucky, United States
MedStar Montgomery Medical Center
Olney, Maryland, United States
Boston Neuro Research Center
Boston, Massachusetts, United States
Parkinson's Research Centers of America - Long Island
Commack, New York, United States
University of Rochester
Rochester, New York, United States
The Medical University of South Carolina
Charleston, South Carolina, United States
Veracity Neuroscience LLC
Memphis, Tennessee, United States
UT Health San Antonio
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, Agarwal P, Aldridge GM, Barboi A, Evidente VGH, Galasko D, Geschwind MD, Gonzalez-Duarte A, Gil R, Gudesblatt M, Isaacson SH, Kaufmann H, Khemani P, Kumar R, Lamotte G, Liu AJ, McFarland NR, Miglis M, Reynolds A, Sahagian GA, Saint-Hillaire MH, Schwartzbard JB, Singer W, Soileau MJ, Vernino S, Yerstein O, Freeman R. Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients With Synucleinopathies. JAMA. 2024 Apr 16;331(15):1298-1306. doi: 10.1001/jama.2024.0792.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MJFF-025208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.